Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.90
NAS:MDCO's Cash-to-Debt is ranked lower than
64% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. NAS:MDCO: 0.90 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MDCO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: No Debt Max: No Debt
Current: 0.9
Equity-to-Asset 0.43
NAS:MDCO's Equity-to-Asset is ranked lower than
77% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:MDCO: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MDCO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.76 Max: 0.89
Current: 0.43
0.41
0.89
Piotroski F-Score: 1
Altman Z-Score: 2.24
Beneish M-Score: -3.07
WACC vs ROIC
2.64%
-35.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -154.75
NAS:MDCO's Operating Margin % is ranked lower than
89% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. NAS:MDCO: -154.75 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MDCO' s Operating Margin % Range Over the Past 10 Years
Min: -88.18  Med: 0.2 Max: 14.87
Current: -154.75
-88.18
14.87
Net Margin % -96.44
NAS:MDCO's Net Margin % is ranked lower than
87% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. NAS:MDCO: -96.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:MDCO' s Net Margin % Range Over the Past 10 Years
Min: -114.16  Med: 0.02 Max: 29.79
Current: -96.44
-114.16
29.79
ROE % -26.00
NAS:MDCO's ROE % is ranked lower than
82% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. NAS:MDCO: -26.00 )
Ranked among companies with meaningful ROE % only.
NAS:MDCO' s ROE % Range Over the Past 10 Years
Min: -42.69  Med: -0.43 Max: 35
Current: -26
-42.69
35
ROA % -11.11
NAS:MDCO's ROA % is ranked lower than
78% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NAS:MDCO: -11.11 )
Ranked among companies with meaningful ROA % only.
NAS:MDCO' s ROA % Range Over the Past 10 Years
Min: -20  Med: -0.32 Max: 24.65
Current: -11.11
-20
24.65
ROC (Joel Greenblatt) % -53.69
NAS:MDCO's ROC (Joel Greenblatt) % is ranked lower than
80% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. NAS:MDCO: -53.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MDCO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -168.9  Med: 26.57 Max: 402.9
Current: -53.69
-168.9
402.9
3-Year Revenue Growth Rate -22.90
NAS:MDCO's 3-Year Revenue Growth Rate is ranked lower than
90% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. NAS:MDCO: -22.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MDCO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.3 Max: 88.5
Current: -22.9
0
88.5
GuruFocus has detected 7 Warning Signs with The Medicines Co $NAS:MDCO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MDCO's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MDCO Guru Trades in Q1 2016

Jim Simons 287,361 sh (+15.39%)
RS Investment Management 1,307,762 sh (+9.10%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Steven Cohen 319,700 sh (-51.30%)
Chuck Royce 50,232 sh (-53.59%)
» More
Q2 2016

MDCO Guru Trades in Q2 2016

First Eagle Investment 555,099 sh (New)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Chuck Royce 50,232 sh (unchged)
Jim Simons Sold Out
RS Investment Management 1,195,810 sh (-8.56%)
Steven Cohen 260,600 sh (-18.49%)
» More
Q3 2016

MDCO Guru Trades in Q3 2016

Jim Simons 8,100 sh (New)
First Eagle Investment 1,020,629 sh (+83.86%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Chuck Royce 45,232 sh (-9.95%)
Steven Cohen 176,900 sh (-32.12%)
» More
Q4 2016

MDCO Guru Trades in Q4 2016

Jim Simons 415,900 sh (+5034.57%)
First Eagle Investment 1,055,029 sh (+3.37%)
Chuck Royce 45,232 sh (unchged)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:NBIX, OTCPK:STDAF, NAS:ENDP, NAS:HZNP, NAS:OPK, NAS:AKRX, NYSE:PTHN, NYSE:TARO, NAS:IRWD, NAS:RDUS, NYSE:VRX, OTCPK:HYPMY, NAS:PCRX, NAS:SUPN, NAS:EGRX, OTCPK:HKMPF, NAS:MNTA, NAS:IPXL, OTCPK:EVTCY, NAS:DEPO » details
Traded in other countries:MZN.Germany,
The Medicines Co is a biopharmaceutical company. The Company markets Angiomax, Cleviprex injectable emulsion, Minocin for injection, Orbactiv, PreveLeakTM and Recothrom Thrombin topical. The Company also sells ready‑to‑use formulation of Argatroban.

The Medicines Co was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.

Top Ranked Articles about The Medicines Co

6 Stocks Traded by Insiders Last Week Officers trade shares of Medicines Co., VBI Vaccines, TransDigm Group, Headwaters, Cooper-Standard, AutoZone
The All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+” and the duration to “December 2016” and All Insider Sales to “$5,000,000+.” Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.84
MDCO's PB Ratio is ranked lower than
73% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MDCO: 4.84 )
Ranked among companies with meaningful PB Ratio only.
MDCO' s PB Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.5 Max: 6.94
Current: 4.84
1.14
6.94
PS Ratio 17.22
MDCO's PS Ratio is ranked lower than
91% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MDCO: 17.22 )
Ranked among companies with meaningful PS Ratio only.
MDCO' s PS Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.91 Max: 17.66
Current: 17.22
0.9
17.66
Current Ratio 3.46
MDCO's Current Ratio is ranked higher than
67% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. MDCO: 3.46 )
Ranked among companies with meaningful Current Ratio only.
MDCO' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 4.01 Max: 10.09
Current: 3.46
0.75
10.09
Quick Ratio 3.12
MDCO's Quick Ratio is ranked higher than
72% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. MDCO: 3.12 )
Ranked among companies with meaningful Quick Ratio only.
MDCO' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.51 Max: 9.44
Current: 3.12
0.75
9.44
Days Inventory 356.65
MDCO's Days Inventory is ranked lower than
95% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. MDCO: 356.65 )
Ranked among companies with meaningful Days Inventory only.
MDCO' s Days Inventory Range Over the Past 10 Years
Min: 72.24  Med: 130.74 Max: 315.65
Current: 356.65
72.24
315.65
Days Sales Outstanding 49.33
MDCO's Days Sales Outstanding is ranked higher than
75% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. MDCO: 49.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDCO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.9  Med: 47.48 Max: 86.14
Current: 49.33
26.9
86.14
Days Payable 85.20
MDCO's Days Payable is ranked higher than
62% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. MDCO: 85.20 )
Ranked among companies with meaningful Days Payable only.
MDCO' s Days Payable Range Over the Past 10 Years
Min: 15.33  Med: 48.79 Max: 109.68
Current: 85.2
15.33
109.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
MDCO's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. MDCO: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDCO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -85.1  Med: -6.4 Max: 0
Current: -8.8
-85.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 47.76
MDCO's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
95% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. MDCO: 47.76 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDCO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.68 Max: 34.62
Current: 47.76
0.84
34.62
Price-to-Median-PS-Value 5.93
MDCO's Price-to-Median-PS-Value is ranked lower than
96% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. MDCO: 5.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDCO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.34 Max: 61.83
Current: 5.93
0.33
61.83
Earnings Yield (Greenblatt) % -1.00
MDCO's Earnings Yield (Greenblatt) % is ranked lower than
78% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. MDCO: -1.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDCO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 4.45 Max: 15.2
Current: -1
0.5
15.2
Forward Rate of Return (Yacktman) % -7.35
MDCO's Forward Rate of Return (Yacktman) % is ranked lower than
81% of the 353 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.48 vs. MDCO: -7.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDCO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.6  Med: 2.2 Max: 5.2
Current: -7.35
-16.6
5.2

More Statistics

Revenue (TTM) (Mil) $209.8
EPS (TTM) $ -3.11
Beta0.02
Short Percentage of Float34.74%
52-Week Range $29.48 - 54.01
Shares Outstanding (Mil)70.79

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 168 108 187 302
EPS ($) -4.15 -4.76 -3.29 -2.14
EPS without NRI ($) -4.15 -4.76 -3.29 -2.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
6 Stocks Traded by Insiders Last Week Dec 12 2016 
Netflix Profit Above Consensus, Panera Bread Boosts Buyback Plan, Medicines Co Cangrelor Well-Recomm Apr 16 2015 
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous... Feb 21 2017
The Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial Results on February... Feb 17 2017
Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co. Feb 15 2017
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise Feb 09 2017
Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides Feb 03 2017
Amgen CEO: Will work with Trump to lower drug prices Feb 02 2017
The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American... Jan 25 2017
The Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : January 23,... Jan 23 2017
ETFs with exposure to The Medicines Co. : January 20, 2017 Jan 20 2017
The Medicines Co LDL-Lowering Drug Positive in Phase II Jan 09 2017
The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing... Jan 08 2017
Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha? Jan 06 2017
[video]Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View Jan 06 2017
These 5 Biotech Stocks Could Be Big Takeover Targets in 2017 Jan 06 2017
The Medicines Co. breached its 50 day moving average in a Bullish Manner : MDCO-US : January 5, 2017 Jan 05 2017
The Medicines Company to Present at J. P. Morgan Healthcare Conference Jan 04 2017
The Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : December 23,... Dec 23 2016
Insider Buying Volume Big as Trump Rally Rolls On: Transdigm, Medicines Company, Medley Capital, W&T... Dec 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)